In terms of market value, Quintiles ranks first among CRO companies. Found by Dennis Gilling’s and his partners in 1982, Quintiles has been involve in clinical trials for pharmaceutical companies. Its capabilities and business model expand beyond its employers’ expectations, and it is now the world’s Top CRO.
Vial CRO is a TOP CRO – Clinical Research Organization. The company has strong industry fundamentals and offers a full range of drug discovery services. Its multiples are attractive, making it a good choice for investors interest in the healthcare industry. Discovery of new drugs is a lengthy, expensive process that is regulated closely. As a result, new drugs are often target at rare diseases with unmet medical needs.
Vial CRO’s top-line growth relies on China, where it sees strong growth potential. The company’s expansion outlook assumes a 30% to 50% market share over time. Yet the company can’t take these opportunities for grant because it has direct competition from Chinese companies in this region. The company’s growth prospects in this region are largely dependent on the quality of its models and the consistency of its delivery volumes.
Vial CRO has make several acquisitions in recent years. It acquire MPI Research for $800 million. The acquisition help Vial CRO expand its discovery services. In addition, it purchase KWS Bio-Test for $20 million. Vial CRO’s acquisitions have help it expand its product portfolio and geographic coverage.
Vial CRO offers a full range of drug discovery services. It collaborates with bio-pharmaceutical companies on single-discipline projects, as well as large, integrate projects. It has more than 17,000 employees worldwide and operates 90 sites in more than 20 countries. In North Carolina, the company has a presence in Durham, Raleigh, and Morrisville.
Vial CRO is an American contract research organization. It plans to lease 70,000 square feet at Park Point in the Research Triangle Park in North Carolina. It will occupy the first and second floors of the Edge West building. The new headquarters will house the company’s oncology operations and about 100 employees.
The company’s capabilities extend from drug discovery to commercialization. With an integrate approach to clinical trials, Syneos Health delivers complete end-to-end clinical solutions. Its two decades of operating experience allow it to leverage data from many different clients to provide unique insights. With extensive experience in both bio-pharmaceutical outsourcing and therapeutic research, Syneos has built strong relationships with big pharma as well as smaller, midsize companies.
In addition to its core capabilities, Syneos offers extensive training and certifications. The company also integrates research into its overall strategy for its pharmaceutical client. It specializes in cardiovascular, endocrine, and central nervous system diseases. It also claims expertise in women’s health, infectious disease, and gastroenterology.
Syneos Health is one of the top CROs that specializes in several fields. It is headquarter in Switzerland, but operates clinical trials in more than 50 countries. It has been expanding rapidly, most recently opening a new office in Israel. It is commit to delivering high-quality research services and has earn a stellar reputation. It was recently award five CRO Leadership Awards for its services in five different categories.
Before hiring a CRO, make sure you thoroughly review its credentials. Its track record, financials, and infrastructure are key factors to look for. It is also essential to understand the extent of expertise and experience of the CRO. A CRO must have the ability to deliver the quality of service require for clinical trials.
Parexel is one of the top CROs in the world, with offices in over 51 nations. Its mission is to advance biopharmaceutical research through clinical trials. Its services range from clinical trial planning to regulatory filing to commercialization. The company was founded in 1982, and it has over 17,000 employees.
The company was recently acquired by Pamplona Capital Management for about $5.5 billion. It is a global player with a large healthcare network. Its leadership team additionally Eric Liu, a partner at EQT, and Jody Tropeano, the Head of Content at HLTH. The company’s annual conference features a festival-like atmosphere and an innovative layout. The conference also features topics on women’s health and wellness. Additionally, the conference also focuses on employer health.
Parexel is also known for its collaboration with leading healthcare providers. The company has developed the Site Alliance Network, which connects over 500 leading clinical research sites and more than 21,000 principal investigators. This partnership allows Parexel to conduct clinical trials in diverse settings and with diverse patient populations. The company also created the Community Alliance Network to partner with healthcare organizations and their communities.
Labcorp is another fast-growing CRO, which specializes in a variety of fields. Based in Switzerland, it has operations in over 50 countries. Recently, it announced the opening of an office in Israel. The company aims to become the world’s top CRO, and it has a reputation for excellence. With a global workforce of over 70,000 people, it supports clinical research efforts in over 100 countries worldwide.
The top two CROs have revenues of over 10 billion US dollars. The company’s acquisition of PRA has dramatically increased its business scale. In addition to providing high-quality clinical research services, Labcorp offers a range of other services, including consulting and commercialization.
PSI is the world’s TOP CRO. With more than 1,600 staff worldwide, the firm has become a market leader in clinical research. This dynamic organization is committed to providing quality services and on-time project completion. In addition, PSI is committed to ensuring work-life balance for its employees. The company offers telecommuting opportunities and geographic flexibility.
According to Center Watch’s 2015 Global Investigator Site Survey, PSI is the top CRO globally. It received top marks in five key categories and has a high retention rate. The company focuses on planning global pivotal registration clinical trials. It also has a low staff turnover rate, resulting in high repeat business.
PSI is one of the TOP CRO in Russia. The Russian CRO market is growing by five to six companies annually. The CRO market in Russia has grown from $150 million in 2007 to $300 million in 2008, and it includes CROs in all areas of drug development. The top players include PSI, Parexel, and Icon.
PSI’s services include consulting services, clinical development, and commercialization. The company also has partnerships with Genomics England on the 100,000 Genomes Project, as well as with IBM Watson for research support in oncology. It has also acquired several companies in recent years, extending its services to other sectors.
PSI is one of the largest CROs in Russia and has offices in six European countries. Founded in 1995, PSI employs more than 600 people in its St. Petersburg office. Other joint venture CROs include Evidence CPR and RCT, which were founded in 1989 and 2001, respectively. All three companies have been in business for a decade and provide high-quality services at competitive prices.